NewTimeSpace丨BioRay Biopharmaceutical, China's Leading Autoimmune Disease Company, Files for Hong Kong IPO
BioRay Biopharmaceutical recently submitted its listing application to the Hong Kong Stock Exchange. According to Frost & Sullivan, the company has ranked first among Chinese pharmaceutical companies by autoimmune disease biologics revenue for two consecutive years since 2023. The prospectus shows it recorded revenue of RMB 1.623 billion and net profit of RMB 91 million in 2024, with a gross margin of 79.2%.
Zhejiang BioRay Biopharmaceutical Co., Ltd. (hereinafter referred to as "BioRay Biopharmaceutical") recently submitted its prospectus to the Hong Kong Stock Exchange, seeking a listing on the Main Board with Huatai International and J.P. Morgan as joint sponsors.
Tags：
- Going Global Weekly Report: Pharma Firms Sealed Licensing Deals at a Fast Pace as Semiconductors and E-Commerce Accelerate toward HK Listings - 20260904
- HK Stock Connect Daily Report: PHANCY Surged Nearly 15%; Hang Seng Index Quarterly Review Effective Today, Goldman Sachs Expects USD 870 Million of Passive Inflows into Tech Hardware - 20260904
- TOYA receives CSRC supplementary information request on overseas listing filing, covering shareholding entrustment, controlling shareholder title disputes and equity incentives
- GLB receives CSRC supplementary information request on overseas listing filing, covering absence of controlling shareholder, SOE procedures and proposed projects
- NANJING LINGXING receives CSRC supplementary information request on overseas listing filing, covering absence of controlling shareholder, ride-hailing compliance and foreign investment access
